ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.